Jefferies Group LLC reaffirmed their hold rating on shares of Genomic Health, Inc. (NASDAQ:GHDX) in a research report released on Thursday. The firm currently has a $33.00 target price on the medical research company’s stock.
GHDX has been the subject of several other reports. Zacks Investment Research cut Genomic Health from a hold rating to a sell rating in a research note on Tuesday, August 1st. Piper Jaffray Companies reissued a hold rating and set a $31.00 target price on shares of Genomic Health in a research note on Thursday, August 3rd. BidaskClub cut Genomic Health from a hold rating to a sell rating in a research note on Friday, August 4th. Canaccord Genuity lowered their target price on Genomic Health from $36.00 to $35.00 and set a buy rating for the company in a research note on Tuesday, August 15th. Finally, Cowen and Company reissued a hold rating and set a $34.00 target price on shares of Genomic Health in a research note on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. Genomic Health presently has an average rating of Hold and an average price target of $32.00.
Shares of Genomic Health (GHDX) traded up 0.87% during midday trading on Thursday, hitting $31.27. The company had a trading volume of 225,418 shares. The company has a 50-day moving average of $30.90 and a 200 day moving average of $31.60. The firm’s market capitalization is $1.08 billion. Genomic Health has a 12 month low of $26.37 and a 12 month high of $33.97.
Genomic Health (NASDAQ:GHDX) last released its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.02). Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The company had revenue of $85.50 million for the quarter, compared to analyst estimates of $86.08 million. During the same period in the previous year, the firm earned ($0.18) earnings per share. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, analysts expect that Genomic Health will post ($0.01) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Equities Focus and is owned by of Equities Focus. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.equitiesfocus.com/2017/09/17/genomic-health-inc-ghdx-earns-hold-rating-from-jefferies-group-llc.html.
In other Genomic Health news, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $32.53, for a total transaction of $162,650.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James J. Vaughn sold 8,000 shares of Genomic Health stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $30.59, for a total value of $244,720.00. The disclosure for this sale can be found here. Insiders have sold a total of 42,642 shares of company stock valued at $1,354,431 over the last ninety days. 46.20% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wetherby Asset Management Inc. lifted its holdings in Genomic Health by 3.7% during the 2nd quarter. Wetherby Asset Management Inc. now owns 8,912 shares of the medical research company’s stock worth $290,000 after buying an additional 317 shares during the last quarter. Dubuque Bank & Trust Co. lifted its holdings in shares of Genomic Health by 8.4% in the 2nd quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after purchasing an additional 379 shares during the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of Genomic Health by 5.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after purchasing an additional 441 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Genomic Health by 0.6% in the 1st quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock valued at $2,789,000 after purchasing an additional 500 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Genomic Health by 3.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock valued at $516,000 after purchasing an additional 520 shares during the last quarter. 88.91% of the stock is owned by institutional investors.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.